Table 1.

Characteristics of patients

Patient
Sex
Age, y
Treatment
WBC count, × 109/L
Rai stage
CD38
Interphase cytogenetics*
1   M   55   None   20   1   –   NA  
2   M   85   Chlorambucil†  68   3/4   NA   NA  
3   M   47   Multiple   40   1   –   Normal  
4‡  NA   NA   NA   NA   NA   NA   NA  
5   F   70   None   60   0   NA   NA  
6   M   47   None   30   1   –   NA  
7   F   54   Chlorambucil§  16   0   +   +12 13q  
8   M   57   None   200   1   NA   13q  
9   M   50   None   37   1   NA   NA  
10   M   75   Multiple∥  100   3/4   –   13q  
11   M   61   None   69   1   +   13q 11q  
12   F   79   Multiple  34   1   NA   NA  
13   F   69   None   107   1   +   Normal  
14   M   52   Fludarabine#  200   2   +   Normal  
15   F   52   None   42   1   NA   NA  
16   F   57   None   300   1   +   +12 t(1;6)  
17   M   75   Multiple**  21   2   +   13q  
18   F   57   None   219   1   –   13q 6q  
19
 		 F
 		 56
 		 None
 		 72
 		 1
 		 +
 		 +12
 
Patient
Sex
Age, y
Treatment
WBC count, × 109/L
Rai stage
CD38
Interphase cytogenetics*
1   M   55   None   20   1   –   NA  
2   M   85   Chlorambucil†  68   3/4   NA   NA  
3   M   47   Multiple   40   1   –   Normal  
4‡  NA   NA   NA   NA   NA   NA   NA  
5   F   70   None   60   0   NA   NA  
6   M   47   None   30   1   –   NA  
7   F   54   Chlorambucil§  16   0   +   +12 13q  
8   M   57   None   200   1   NA   13q  
9   M   50   None   37   1   NA   NA  
10   M   75   Multiple∥  100   3/4   –   13q  
11   M   61   None   69   1   +   13q 11q  
12   F   79   Multiple  34   1   NA   NA  
13   F   69   None   107   1   +   Normal  
14   M   52   Fludarabine#  200   2   +   Normal  
15   F   52   None   42   1   NA   NA  
16   F   57   None   300   1   +   +12 t(1;6)  
17   M   75   Multiple**  21   2   +   13q  
18   F   57   None   219   1   –   13q 6q  
19
 		 F
 		 56
 		 None
 		 72
 		 1
 		 +
 		 +12
 

WBC indicates white blood cell; NA, information not available.

*

The only patients from which variable heavy chain (VH) gene mutational status was available were patients 8 and 10, both having VH unmutated

†

Rituximab, cyclophosphamide, vincristine, and prednisone (2000)

‡

Patient 4 entered the study in condition of anonymity

§

Treatment received in 2003 and 2004

∥

Fludarabine/mitoxantrone (1999); cyclophosphamide, vincristine, and prednisone/rituximab (2003); alemtuzumab (2003)

Chlorambucil (1992–2000); rituximab, cyclophosphamide, vincristine, and prednisone (2002)

#

Treatment received in 2001

**

Pentostatin/cyclophosphamide/rituximab (2003 and 2004)

View Large